Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1173 participants.
Also called NCT01274559
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,173 participants
- Sponsor
- Registry
-
NCT01274559 -
CTRI/2012/08/002857 -
2010-021627-27
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01274559. Randomized; double masking; primary purpose treatment. Start 2011-03-01 (actual); primary completion 2013-02-26 (actual). Results posted on 2014-03-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
- Condition
- Primary Hypercholesterolemia
- Condition
- Mixed Dyslipidemia
- Intervention (Drug)
- Extended-release niacin/laropiprant (ERN/LRPT)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01274559- Content hash
871e643062f575c8584c54293be3a2af74c78eca7e34620c98b273c63dcd4f25